EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs . Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data

Sarah Sharman Moser, Lior Apter, Josie Solomon, Gabriel Chodick, Miriana Wollner, Nava Siegelmann-Danieli

Anticancer Research · 2024

DOI: 10.21873/anticanres.16809 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Anticancer Research, 2024. Verfasst von Sarah Sharman Moser und 5 weiteren Autor:innen. Beteiligte Einrichtung: Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel; moser_sa@mac.org.il. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsTyrosine Kinase InhibitorsAgedFemaleHumansMaleAniline CompoundsErbB ReceptorsMutationAcrylamidesIndolesPyrimidines

Stichwörter der Autor:innen

EGFR mutationNon-small cell lung cancerosimertinibretrospective database studysurvival analysistyrosine kinase inhibitors

Substanzen

Aniline CompoundsErbB ReceptorsTyrosine Kinase InhibitorsEGFR protein, humanosimertinibAcrylamidesIndolesPyrimidines

Autor:innen und Institutionen

  • Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel; moser_sa@mac.org.il.
  • Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, Tel Aviv, Israel.
  • Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • The School of Pharmacy, Joseph Banks Laboratories, University of Lincoln, Lincoln, U.K.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Institute of Oncology, Rambam Medical Centre, Haifa, Israel.

Zitieren

APA

Moser, S. S., Apter, L., Solomon, J., Chodick, G., Wollner, M., & Siegelmann-Danieli, N. (2024). Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs . Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data. Anticancer Research. https://doi.org/10.21873/anticanres.16809

Vancouver

Moser SS, Apter L, Solomon J, Chodick G, Wollner M, Siegelmann-Danieli N. Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs . Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data. Anticancer Research. 2024. doi:10.21873/anticanres.16809

BibTeX
@article{Moser2024,
  author = {Moser, Sarah Sharman and Apter, Lior and Solomon, Josie and Chodick, Gabriel and Wollner, Miriana and Siegelmann-Danieli, Nava},
  title = {Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs . Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.16809}
}
Kostenlos starten →